Metabolomics reveals the effect of Xuefu Zhuyu Decoction on plasma metabolism in rats with acute traumatic brain injury
Metrics: PDF 1466 views | HTML 1784 views | ?
Dandan Feng1, Zian Xia1, Jing Zhou1, Hongmei Lu2, Chunhu Zhang1, Rong Fan1, Xingui Xiong1, Hanjin Cui1, Pingping Gan3, Wei Huang1, Weijun Peng4, Feng He5, Zhiming Wang5, Yang Wang1 and Tao Tang1
1Institute of Integrative Chinese Medicine, Xiangya Hospital, Central South University, Changsha 410008, P.R. China
2Research Center of Modernization of Traditional Chinese Medicines, College of Chemistry and Chemical Engineering, Central South University, Changsha 410083, P.R. China
3Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, P.R. China
4Department of Integrated Chinese and Western Medicine, The Second Xiangya Hospital, Central South University, Changsha 410011, P.R. China
5Department of Hepatobiliary Surgery, Xiangya Hospital, Central South University, Changsha 410008, P.R. China
Yang Wang, email: firstname.lastname@example.org
Tao Tang, email: email@example.com
Keywords: metabolomics, acute traumatic brain injury, traditional Chinese medicine, Xuefu Zhuyu Decoction, gas chromatography/mass spectrometry
Received: February 21, 2017 Accepted: September 03, 2017 Published: October 16, 2017
Xuefu Zhuyu Decoction (XFZY), an important traditional Chinese herbal formula, has been reported effective on traumatic brain injury (TBI) in rats. However, its cerebral protection mechanism has not been clarified at the metabolic level. This work aims to explore the global metabolic characteristics of XFZY in rats during the acute phase of TBI on days 1 and 3. A plasma metabolomics method based on gas chromatography-mass spectrometry coupled with univariate analysis and multivariate statistical analysis was performed in three groups (Sham, Vehicle, XFZY). Then, a pathway analysis using MetaboAnalyst 3.0 was performed to illustrate the pathways of therapeutic action of XFZY in TBI. XFZY treatment attenuates neurological dysfunction and cortical lesion volume post-injury on day 3, and reverses the plasma metabolite abnormalities (glutamic acid, lactic acid, 3-hydroxybutyric acid, and ribitol, etc.). These differential metabolites are mainly involved in D-glutamine and D-glutamate metabolism, alanine, aspartate and glutamate metabolism, and inositol phosphate metabolism. Our study reveals potential biomarkers and metabolic networks of acute TBI and neuroprotection effects of XFZY, and shows this metabolomics approach with MetaboAnalyst would be a feasible way to systematically study therapeutic effects of XFZY on TBI.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.